FAM151A

Across TCGA pan-cancer cohorts, FAM151A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM151A data layer compared with 25 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher FAM151A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM151A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, BLCA, and UCEC are the cancer types where FAM151A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.667	<.001	33	view →
BLCA	OS	Median	All	0.218	0.610	.010	15	view →
UCEC	DFS	Median	All	0.926	0.619	.022	10	view →
SARC	OS	Median	All	0.162	0.767	.002	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM151A–STAD (OS)

Open the STAD breakdown →